Kingworld Medicines Group Limited

SEHK:1110 Rapport sur les actions

Capitalisation boursière : HK$290.6m

Kingworld Medicines Group Croissance future

Future contrôle des critères 0/6

Nous ne disposons actuellement pas d'une couverture d'analyste suffisante pour prévoir la croissance et les revenus de Kingworld Medicines Group.

Informations clés

n/a

Taux de croissance des bénéfices

n/a

Taux de croissance du BPA

Healthcare croissance des bénéfices22.3%
Taux de croissance des recettesn/a
Rendement futur des capitaux propresn/a
Couverture par les analystes

None

Dernière mise à journ/a

Mises à jour récentes de la croissance future

Recent updates

Kingworld Medicines Group (HKG:1110) Takes On Some Risk With Its Use Of Debt

Oct 04
Kingworld Medicines Group (HKG:1110) Takes On Some Risk With Its Use Of Debt

Kingworld Medicines Group (HKG:1110) Is Increasing Its Dividend To CN¥0.0338

May 31
Kingworld Medicines Group (HKG:1110) Is Increasing Its Dividend To CN¥0.0338

Even With A 26% Surge, Cautious Investors Are Not Rewarding Kingworld Medicines Group Limited's (HKG:1110) Performance Completely

May 22
Even With A 26% Surge, Cautious Investors Are Not Rewarding Kingworld Medicines Group Limited's (HKG:1110) Performance Completely

Investors Shouldn't Be Too Comfortable With Kingworld Medicines Group's (HKG:1110) Earnings

Apr 29
Investors Shouldn't Be Too Comfortable With Kingworld Medicines Group's (HKG:1110) Earnings

Kingworld Medicines Group (HKG:1110) Will Pay A Larger Dividend Than Last Year At CN¥0.0338

Apr 23
Kingworld Medicines Group (HKG:1110) Will Pay A Larger Dividend Than Last Year At CN¥0.0338

A Look At The Fair Value Of Kingworld Medicines Group Limited (HKG:1110)

Mar 22
A Look At The Fair Value Of Kingworld Medicines Group Limited (HKG:1110)

The Return Trends At Kingworld Medicines Group (HKG:1110) Look Promising

Nov 30
The Return Trends At Kingworld Medicines Group (HKG:1110) Look Promising

Slowing Rates Of Return At Kingworld Medicines Group (HKG:1110) Leave Little Room For Excitement

Aug 17
Slowing Rates Of Return At Kingworld Medicines Group (HKG:1110) Leave Little Room For Excitement

Kingworld Medicines Group (HKG:1110) Will Pay A Larger Dividend Than Last Year At CN¥0.0247

May 30
Kingworld Medicines Group (HKG:1110) Will Pay A Larger Dividend Than Last Year At CN¥0.0247

The Returns At Kingworld Medicines Group (HKG:1110) Aren't Growing

May 11
The Returns At Kingworld Medicines Group (HKG:1110) Aren't Growing

Kingworld Medicines Group (HKG:1110) Is Increasing Its Dividend To CN¥0.0247

Apr 03
Kingworld Medicines Group (HKG:1110) Is Increasing Its Dividend To CN¥0.0247

Returns On Capital At Kingworld Medicines Group (HKG:1110) Paint A Concerning Picture

Feb 07
Returns On Capital At Kingworld Medicines Group (HKG:1110) Paint A Concerning Picture

A Look At The Fair Value Of Kingworld Medicines Group Limited (HKG:1110)

Oct 07
A Look At The Fair Value Of Kingworld Medicines Group Limited (HKG:1110)

Kingworld Medicines Group's (HKG:1110) Returns On Capital Not Reflecting Well On The Business

Jul 05
Kingworld Medicines Group's (HKG:1110) Returns On Capital Not Reflecting Well On The Business

Kingworld Medicines Group (HKG:1110) Is Increasing Its Dividend To HK$0.024

Apr 27
Kingworld Medicines Group (HKG:1110) Is Increasing Its Dividend To HK$0.024

We Like These Underlying Return On Capital Trends At Kingworld Medicines Group (HKG:1110)

Aug 17
We Like These Underlying Return On Capital Trends At Kingworld Medicines Group (HKG:1110)

Kingworld Medicines Group (HKG:1110) Seems To Use Debt Rather Sparingly

Apr 24
Kingworld Medicines Group (HKG:1110) Seems To Use Debt Rather Sparingly

Returns On Capital Are Showing Encouraging Signs At Kingworld Medicines Group (HKG:1110)

Mar 29
Returns On Capital Are Showing Encouraging Signs At Kingworld Medicines Group (HKG:1110)

Kingworld Medicines Group's (HKG:1110) Shareholders Are Down 46% On Their Shares

Mar 08
Kingworld Medicines Group's (HKG:1110) Shareholders Are Down 46% On Their Shares

Are Insiders Buying Kingworld Medicines Group Limited (HKG:1110) Stock?

Feb 15
Are Insiders Buying Kingworld Medicines Group Limited (HKG:1110) Stock?

Should You Or Shouldn't You: A Dividend Analysis on Kingworld Medicines Group Limited (HKG:1110)

Jan 25
Should You Or Shouldn't You: A Dividend Analysis on Kingworld Medicines Group Limited (HKG:1110)

Will the Promising Trends At Kingworld Medicines Group (HKG:1110) Continue?

Dec 18
Will the Promising Trends At Kingworld Medicines Group (HKG:1110) Continue?

We Think Kingworld Medicines Group (HKG:1110) Can Stay On Top Of Its Debt

Dec 05
We Think Kingworld Medicines Group (HKG:1110) Can Stay On Top Of Its Debt

What We Learned About Kingworld Medicines Group's (HKG:1110) CEO Compensation

Nov 22
What We Learned About Kingworld Medicines Group's (HKG:1110) CEO Compensation

Dans cette section, nous présentons généralement des projections de croissance du chiffre d'affaires et des bénéfices basées sur les estimations consensuelles d'analystes professionnels afin d'aider les investisseurs à comprendre la capacité de l'entreprise à générer des bénéfices. Mais comme Kingworld Medicines Group n'a pas fourni suffisamment de données passées et n'a pas de prévisions d'analystes, ses bénéfices futurs ne peuvent pas être calculés de manière fiable en extrapolant les données passées ou en utilisant les prévisions des analystes.

Il s'agit d'une situation assez rare car 97% des entreprises couvertes par SimplyWall St disposent de données financières passées.

Prévisions de croissance des bénéfices et des revenus

SEHK:1110 - Estimations futures des analystes et données financières antérieures (CNY Millions )
DateRecettesLes revenusFlux de trésorerie disponibleCash from OpMoy. Nombre d'analystes
6/30/20241,0523144117N/A
3/31/20241,06535-1080N/A
12/31/20231,07938-6342N/A
9/30/20231,08537-15110N/A
6/30/20231,0913634177N/A
3/31/20231,0242964182N/A
12/31/20229582393187N/A
9/30/20229052966159N/A
6/30/20228523540131N/A
3/31/20228503331106N/A
12/31/2021847302381N/A
9/30/20218582676111N/A
6/30/202186821129141N/A
3/31/202180717121132N/A
12/31/202074512114124N/A
9/30/2020749169099N/A
6/30/2020752206674N/A
3/31/20208653295103N/A
12/31/201997843124133N/A
9/30/20191,010457988N/A
6/30/20191,041463444N/A
3/31/20191,060444253N/A
12/31/20181,079415162N/A
9/30/20181,079496085N/A
6/30/20181,0795670108N/A
3/31/20181,05554N/A90N/A
12/31/20171,03151N/A72N/A
9/30/20171,08850N/A58N/A
6/30/20171,14549N/A43N/A
3/31/20171,09948N/A20N/A
12/31/20161,05447N/A-4N/A
9/30/201690941N/A20N/A
6/30/201676435N/A44N/A
3/31/201673934N/A74N/A
12/31/201571432N/A103N/A
9/30/201571134N/A56N/A
6/30/201570836N/A10N/A
3/31/201568437N/A2N/A
12/31/201466038N/A-5N/A
9/30/201464043N/A-21N/A
6/30/201461948N/A-38N/A
3/31/201458748N/A-44N/A
12/31/201355547N/A-50N/A

Prévisions de croissance des analystes

Taux de revenus par rapport au taux d'épargne: Données insuffisantes pour déterminer si la croissance des bénéfices prévue de 1110 est supérieure au taux d'épargne ( 2.3% ).

Bénéfices vs marché: Données insuffisantes pour déterminer si les bénéfices de 1110 devraient croître plus rapidement que le marché Hong Kong

Croissance élevée des bénéfices: Données insuffisantes pour déterminer si les bénéfices de 1110 devraient augmenter de manière significative au cours des 3 prochaines années.

Chiffre d'affaires vs marché: Données insuffisantes pour déterminer si les revenus de 1110 devraient croître plus rapidement que le marché Hong Kong.

Croissance élevée des revenus: Données insuffisantes pour déterminer si les revenus de 1110 devraient croître plus rapidement que 20% par an.

Prévisions de croissance du bénéfice par action

Rendement futur des capitaux propres

ROE futur: Données insuffisantes pour déterminer si le retour sur capitaux propres de 1110 devrait être élevé dans 3 ans

Découvrir les entreprises en croissance

7D

1Y

7D

1Y

7D

1Y